Tower Research Capital LLC (Trc) Unicycive Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $5.8 Billion
- Q2 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 18,485 shares of UNCY stock, worth $7,763. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,485
Previous 7,678
140.75%
Holding current value
$7,763
Previous $10,000
10.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding UNCY
# of Institutions
25Shares Held
17.4MCall Options Held
0Put Options Held
0-
Vivo Capital, LLC Palo Alto, CA3.47MShares$1.46 Million0.26% of portfolio
-
Logos Global Management LP San Francisco, CA3.47MShares$1.46 Million0.16% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT2.82MShares$1.18 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.63MShares$1.11 Million0.02% of portfolio
-
Bvf Inc San Francisco, CA2.2MShares$924,0000.03% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $6.32M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...